Table 3 A list of lung cancer indicators with the obtained results in years 2019–2021

F_0^a

Multidisciplinary tumourboards assess the completeness of the diagnostics^a

10,793

0%

8%

5%

5%

F_1

The percentage of deaths within one year from the diagnosis of a malignant neoplasm, correlated to tumour stage

505

330

1310

1273

0%

I 1%

II 2%

III 11%

IV 29%

I 4%

II 15%

III 30%

IV 51%

I 4%

II 14%

III 37%

IV 59%

F_2

The percentage of deaths within 30 days from the date of surgery, correlated to tumour stage

362

201

545

492

0%

I 0%

II 0%

III 0%

IV 0%

I 0%

II 0%

III 1%

IV 5%

I 0,3%

II 1%

III 2%

IV 6%

F_3

Percentage of deaths within 30 days from the end of chemotherapy, correlated to tumour stage

71

139

740

665

0%

I 0%

II 0%

III 6%

IV 14%

I 4%

II 4%

III 11%

IV 20%

I 3%

II 4%

III 12%

IV 21%

F_4

Percentage of deaths within 30 days from the end of palliative radiotherapy, correlated to tumour stage

7

17

108

198

0%

I -

II-

III 0%

IV 25%

I -

II 0%

III 15%

IV 21%

I 28%^b

II 0%

III 13%

IV 22%

F_5

Percentage of patients requiring hospitalisation due to complications after surgical treatment

2205

0%

1%

1%

5%

F_6

Percentage of patients requiring hospitalisation due to complications after radiotherapy

50

56

316

265

0%

I 0%

II 0%

III 0%

IV 0%

I 0%

II 0%

III 0%

IV 0%

I 0%

II 0%

III 0%

IV 0%

F_7

Percentage of patients requiring hospitalisation due to complications after systemic treatment (after 30, 60, 90 days)

1748

1748

1748

0%

30 d5%

60 d5%

90 d5%

30 d4%

60 d4%

90 d4%

30 d2%

60 d2%

90 d2%

F_8

Percentage of patients who received chemotherapy during inpatient hospitalisation (according to the WHO ECOG)

8818^c

156

20%^d

WHO 0–2 84%

WHO 3–4 9%

WHO 0–2 74%

WHO 3–4 85%

WHO 0–2 54%

WHO 3–4 79%

F_9

Percentage of stage III and IV cancer patients

2417

2417

0%

III 35%

IV 32%

III 37%

IV 35%

III 37%

IV 36%

F_10

Assessment of the completeness of a pathological exam

2167

1857

0%

0%

initial

diagnostics0%

in-depth 0%

diagnostics

initial

diagnostics0%

in-depth 0,5% diagnostics

initial

diagnostics0%

in-depth 0,3%

diagnostics

F_11_2

Percentage of patients with genetic and molecular testing for predictive factors (lung cancer)^e

225

211

100%

100%

III 33%

IV 77%

III 40%

IV 59%

III 35%

IV 59%

F_12_2

The percentage of surgical procedures performed with minimally invasive surgery (lung cancer)

724

100%

44%

49%

58%

F_13

Median time elapsed from the date of registration of the patient for a diagnostic (imaging or pathomorphological) exam to the date of obtaining the result of this exam^a

N/A

0 days (d)

PET-CT 7 d

H/P 7 d

PET-CT 12 d

H/P 18 d

PET-CT 24 d

H/P 14 d

F_14

Percentage of repeated diagnostic tests over a 6-week period (computed tomography, endoscopy, biopsy, pathomorphological assessment, molecular assessment), shown for each participating centre by tumour type and test type

3103

1423

194

1092

3822

0%

CT 0%

Biopsy 0%

MolecularN/A

Endoscopy0%

H/P 0%

CT 0%

Biopsy 0%

Molecular0%

Endoscopy0%

H/P 0%

CT 0%

Biopsy 0%

Molecular0%

Endoscopy 0%

H/P 0,05%

F_15

Percentage of repeated surgical treatments for diagnoses other than breast cancer

2205

0%

2%

2%

6%

F_22†

Percentage of patients with suspected lung cancer consulted by a pulmonologist within 14 working days from the date of registering the referral with the service provider

62

100%

N/A

87%

92%

F_23

The proportion of patients with mediastinal lymphadenopathy greaterthan 10 mm who underwent EBUS-TBNA

217

100%

44%

60%

67%

F_24†

The proportion of patients with suspected lung cancer and pleural effusion diagnosed with fluid aetiology

25

100%

N/A

4%

8%

F_25‡

The proportion of patients with stage III non-small-cell lung cancer who received concurrent chemoradiotherapy

516

100%

3%

1%

6%

F_31

Percentage of diagnostic tests requiring redescription or reverification of the material over a 6-week period (computed tomography, pathomorphological assessment, molecular assessment), shown for each participating centre by tumour type and test type

3103

194

3822

0%

CT 0%

Molecular0%

H/P 0%

CT 0%

Molecular0%

H/P 0%

CT 0%

Molecular 0%

H/P 0%